R/R MM)患者的预后较差, 目前FDA已批准了两种靶向B细胞成熟抗原(anti-B-cell maturation antigen, BCMA)的CAR-T细胞产品用于治疗MM, 包括2021年3月批准的idecabtagene vicleucel(Ide-cel, Abecma®, 也称为bb2121)和2022年3月的中国首个获FDA批准的CAR...
Anti-CD19 CAR T cell therapy with axi-cel and liso-cel is approved in the second line (2L) for patients (pts) with large B-cell lymphoma (LBCL) relapses within 12 months (mo) of or refractory to frontline therapy (early R/R). However, limited real-world data on CAR T outcomes ...
Chimeric antigen receptor (CAR) T cells have been dominating the C> field for years, resulting in the approval and commercialization of Kymriah, the first therapy of this kind, in 2017. CAR-T cell therapy development has revolutionized the treatment of certain cancers and continues to be an ...
Fig. 4: Engineering strategies to enhance CAR T cell therapy for solid tumors. - 图片说明 ◉ 通过靶向多种抗原,使用双价串联或环状CAR,汇集单一CAR T细胞,或改造NKT和γδ T细胞,可以解决肿瘤异质性和免疫逃逸问题。◉ 通过工程化使其表达趋化因子受体或将TME作为目标(例如FAP),可以改善CAR T细胞向肿瘤...
[1]643P-Efficacy of CAR-T therapy for relapse or refractory multiple myeloma in the Chinese population: A systematic literature review and meta-analysis. [2]298P-Stable, controllable, and scalable manufacturing of B7-H3...
Car T-Cell Therapy Market Overview The global CAR T-cell therapy market size is projected to grow from USD 4.6 billion in 2024 to USD 15.2 billion by 2035, growing at a CAGR of 11.4% during the period, till 2035. To learn more about this report, request a free sample copy The new ...
Epub 2022 Oct 22. PMID: 36280438; PMCID: PMC9790040. [3]Taylor MR, Steineck A, Lahijani S, et al. Biobehavioral Implications of Chimeric Antigen Receptor T-cell Therapy: Current State and Future Directions. Transplant Cell Ther. 2023 Jan;29(1):19-26. doi: 10.1016/j.jtct.2022.09.029....
4.Upadhaya S, Partridge T, Monica S et al. Landscape of cancer cell therapies: trends and real-world data. Nat Rev Drug Discovery. 2022 5. Urvi P, John A, Bipin N et al. CAR T cell therapy in solid tumors: A review of current clinical trials. eJHaem. 2022;3(Suppl. 1):24–...
[1]FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies | FDA [2]Parikh RH, Lonial S. Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data an...
近期,Cancer Treatment and Research Communications杂志发布了一篇由高博临床研究策略研究院撰写的关于通用型嵌合抗原受体T细胞(CAR-T)疗法研究现状与技术分析的综述文章Universal chimeric antigen receptor T cell therapy — The future of cell therapy: A review providing clinical evidence,从通用型CAR-T细胞疗法的起...